CCIA
ARCT icon

Campbell & Co Investment Adviser’s Arcturus Therapeutics ARCT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,920
Closed -$301K – 1040
2024
Q1 		$301K Sell
8,920
-20,466
-70% -$725K 0.03% 901
2023
Q4 		$927K Buy
+29,386
New +$698K 0.08% 421

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Campbell & Co Investment Adviser's ARCT Position: Q2 2024 in Review

Campbell & Co Investment Adviser sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 8,920 shares — an estimated $301K sold.

Campbell & Co Investment Adviser first reported a position in ARCT in Q4 2023 and held it in 2 quarters. The position peaked at $927K in Q4 2023. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Campbell & Co Investment Adviser reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 8,920 Arcturus Therapeutics shares in Q2 2024, an estimated $301K.
  • Campbell & Co Investment Adviser first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Arcturus Therapeutics position peaked at $927K in Q4 2023.
  • 170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2024, filed 13 Aug 2024.